T1	p 325 370	of 95 patients with atherosclerotic disease .
T2	i 27 31	acid
T3	i 58 70	lipid esters
T4	i 78 102	lipid-lowering treatment
T5	i 108 142	diet , clofibrate and niceritrol .
T6	i 187 197	clofibrate
T7	i 263 275	lipid esters
T8	i 478 527	clofibrate or niceritrol , a nicotinic acid ester
T9	i 647 679	diet , clofibrate and niceritrol
T10	i 778 784	esters
T11	i 942 979	monounsaturated fatty acids secreased
T12	i 988 1015	polyunsaturated fatty acids
T13	i 1268 1278	clofibrate
T14	i 1285 1295	niceritrol
T15	i 1360 1370	Clofibrate
T16	i 1418 1439	monounsaturated fatty
T17	i 1498 1504	esters
T18	i 1597 1605	linoleic
T19	i 1646 1652	esters
T20	i 1738 1744	esters
T21	i 1862 1873	fatty acids
T22	i 1905 1915	clofibrate
T23	i 1961 1981	clofibrate treatment
T24	i 2026 2046	polyunsaturated fats
T25	i 2099 2126	monounsaturated fatty acids
T26	i 2147 2153	esters
T27	i 2206 2221	polyunsaturated
T28	i 2236 2247	fatty acids
T29	i 2283 2293	clofibrate
T30	i 2347 2362	polyunsaturated
T31	o 58 63	lipid
T32	o 160 183	proportion of linoleate
T33	o 187 197	clofibrate
T34	o 232 248	acid composition
T35	o 256 268	plasma lipid
T36	o 706 730	serum lipid reductions .
T37	o 735 757	fatty acid composition
T38	o 765 784	plasma lipid esters
T39	o 859 876	dietary adherence
T40	o 988 1015	polyunsaturated fatty acids
T41	o 1095 1100	acids
T42	o 1122 1133	cholesterol
T43	o 1145 1158	triglycerides
T44	o 1335 1370	fatty acid composition . Clofibrate
T45	o 1434 1445	fatty acids
T46	o 1486 1524	cholesterol esters , triglycerides and
T47	o 1586 1607	content of linoleic (
T48	o 1613 1621	2 ) acid
T49	o 1634 1672	cholesterol esters and triglycerides .
T50	o 1682 1696	2/18 : 1 ratio
T51	o 1732 1744	lipid esters
T52	o 1770 1779	P/S ratio
T53	o 2363 2366	fat